17321-20-9

Basic information

• Product Name: 3-CHLORO-6-ETHOXYPYRIDAZINE
• Synonyms: 3-CHLORO-6-ETHOXYPYRIDAZINE;3-chloro-6-ethoxypyridazine(SALTDATA: FREE);NSC 94042;Pyridazine, 3-chloro-6-ethoxy-
• CAS NO: 17321-20-9
• Molecular Formula: C₆H₇ClN₂O
• Molecular Weight: 158.58558
• Mol File: 17321-20-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 60-62℃
• Boiling Point: 293.1°Cat760mmHg
• Flash Point: 131.1°C
• Appearance: /
• Density: 1.235
• Vapor Pressure: 0.00308mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.82±0.10(Predicted)
• CAS DataBase Reference: 3-CHLORO-6-ETHOXYPYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-6-ETHOXYPYRIDAZINE(17321-20-9)
• EPA Substance Registry System: 3-CHLORO-6-ETHOXYPYRIDAZINE(17321-20-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 17321-20-9(Hazardous Substances Data)

Usage

General Description

3-Chloro-6-Ethoxypyridazine is a chemical compound belonging to the pyridazine class that has a complex aromatic ring in its structure. 3-CHLORO-6-ETHOXYPYRIDAZINE possesses interesting features that are being explored for their potential uses in various industrial, pharmaceutical, and scientific applications. The chemical's unique structure makes it intriguing for chemists and researchers, who take advantage of the 3-chloro and 6-ethoxy groupings to further manipulate the compound for different purposes. As with all chemicals, handling of 3-Chloro-6-Ethoxypyridazine should be done with care, observing all necessary safety precautions.

InChI:InChI=1/C6H7ClN2O/c1-2-10-6-4-3-5(7)8-9-6/h3-4H,2H2,1H3

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 

Downstream Products

• 748141-86-8 1-[6-(ethyloxy)pyrazolo[1,5-b]pyridazin-3-yl]ethanone 
• 62567-44-6 3-(ethyloxy)pyridazine 
• 19064-67-6 6-chloro-2H-pyridazin-3-one 

Relevant articles and documents

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

Quinoxaline studies. 23. Potential antimalarials. Substituted 5,8-dimethoxy-6-[N-(omega-dimethylaminoalkyl)amino]quinoxalines were prepared: the first series with identical 2,3-substituents H, CH3, C6H5, C6H4-4-Cl, and CH2C6H5; and the second with identical styryl groups CH=CHC6H5, CH=CHC6H4-4-Cl, CH=CHC6H3-3,4-Cl2, CH=CHC6H4-4-F, CH=CHC6H4-4-CF3, and CH=CHC6H4-4-NO2. None of the substances

3-Hydrazinopyridazines substituted in position 6 with a primary amine, secondary amine, or an alkoxy group were synthesized and screened for antihypertensive activity. In general, the 6-dialklamino derivatives are the most active; the (2-hydroxypropyl)methylamino chain provides the best combination of high antihypertensive activity and toxicity.